P Laurent-Puig

Summary

Publications

  1. doi request reprint [Colorectal oncogenesis]
    P Laurent-Puig
    Universite Paris Descartes, UMR S775, pole de biologie, Hôpital Européen Georges Pompidou AP HP, Paris, France
    Bull Cancer 97:1311-21. 2010
  2. pmc Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience
    Hélène Blons
    UMR S775, INSERM, Paris, France
    PLoS ONE 8:e68945. 2013
  3. pmc Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
    Laetitia Marisa
    Cartes d Identité des Tumeurs program, Ligue Nationale Contre Cancer, Paris, France
    PLoS Med 10:e1001453. 2013
  4. pmc TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma
    Karine Pallier
    UMR S775, INSERM, Paris, France
    PLoS ONE 7:e29954. 2012
  5. doi request reprint Mutations and response to epidermal growth factor receptor inhibitors
    Pierre Laurent-Puig
    Université Paris Descartes and INSERM, U775, Bases Moléculaires de la Réponse aux Xénobiotiques, Paris, France
    Clin Cancer Res 15:1133-9. 2009
  6. doi request reprint Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  7. ncbi request reprint Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population
    S Olschwang
    Laboratoire de Génétique Moléculaire des Tumeurs, Institut Curie, Paris, France
    Hum Genet 86:369-70. 1991
  8. ncbi request reprint Sequence of molecular genetic events in colorectal tumorigenesis
    P Laurent-Puig
    Laboratoire de Toxicologie Moléculaire, INSERM U490, Paris, France
    Eur J Cancer Prev 8:S39-47. 1999
  9. ncbi request reprint KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
  10. ncbi request reprint [Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas]
    S Olschwang
    INSERM U434, CEPH, Paris, France
    Pathol Biol (Paris) 54:215-29. 2006

Detail Information

Publications42

  1. doi request reprint [Colorectal oncogenesis]
    P Laurent-Puig
    Universite Paris Descartes, UMR S775, pole de biologie, Hôpital Européen Georges Pompidou AP HP, Paris, France
    Bull Cancer 97:1311-21. 2010
    ..The RAS-MAP kinase pathway is activated by KRAS mutations in CIN tumors or by BRAF mutations in MSI tumors. The p53 pathway is inactivated by TP53 inactivation in CIN tumors or by BAX inactivating mutations in MSI tumors...
  2. pmc Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience
    Hélène Blons
    UMR S775, INSERM, Paris, France
    PLoS ONE 8:e68945. 2013
    ..Concurrently, a nationwide external quality assessment for KRAS testing (MOKAECM) was granted to analyze reproducibility and costs...
  3. pmc Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
    Laetitia Marisa
    Cartes d Identité des Tumeurs program, Ligue Nationale Contre Cancer, Paris, France
    PLoS Med 10:e1001453. 2013
    ..The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses...
  4. pmc TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma
    Karine Pallier
    UMR S775, INSERM, Paris, France
    PLoS ONE 7:e29954. 2012
    ....
  5. doi request reprint Mutations and response to epidermal growth factor receptor inhibitors
    Pierre Laurent-Puig
    Université Paris Descartes and INSERM, U775, Bases Moléculaires de la Réponse aux Xénobiotiques, Paris, France
    Clin Cancer Res 15:1133-9. 2009
    ..Furthermore, our understanding of the mechanism of the EGFR network activation provides new hypotheses on potential new anticancer drugs that may be effective...
  6. doi request reprint Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  7. ncbi request reprint Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population
    S Olschwang
    Laboratoire de Génétique Moléculaire des Tumeurs, Institut Curie, Paris, France
    Hum Genet 86:369-70. 1991
    ..We could find no evidence that this polymorphism is associated with a marked predisposition to colorectal cancer...
  8. ncbi request reprint Sequence of molecular genetic events in colorectal tumorigenesis
    P Laurent-Puig
    Laboratoire de Toxicologie Moléculaire, INSERM U490, Paris, France
    Eur J Cancer Prev 8:S39-47. 1999
    ..In the p53 pathway LOH-positive tumours showed frequent p53 mutation, whereas MSI-positive tumours demonstrated BAX (BCL-2-associated X protein)-inactivating mutation. These alterations contribute to the adenoma-carcinoma transition...
  9. ncbi request reprint KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...
  10. ncbi request reprint [Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas]
    S Olschwang
    INSERM U434, CEPH, Paris, France
    Pathol Biol (Paris) 54:215-29. 2006
    ..HNPCC syndrome is responsible for 5% of colorectal cancers. Identification and management of this disease are part of a multidisciplinary procedure...
  11. ncbi request reprint Somatically acquired genetic alterations in flat colorectal neoplasias
    S Olschwang
    INSERM U434, C E P H, Paris, France
    Int J Cancer 77:366-9. 1998
    ..With the exception of a low KRAS mutation rate, flat adenomas appear to follow tumorigenesis pathways very similar to those identified in exophytic adenomas and carcinomas...
  12. doi request reprint [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view]
    H Blons
    INSERM, UMR S775, 75006 Paris, France
    Bull Cancer 96:S47-56. 2009
    ..KRAS testing is the first predictive genetic test in a frequent solid tumour, the establishment of a QA-program can serve as a future example for the introduction of other markers based on tumour genetic alterations...
  13. doi request reprint [Biological criteria of eligibility for a treatment against EGFR]
    Pierre Laurent-Puig
    Inserm UMR S775, Bases Moléculaires de la Réponse aux Xénobiotiques, Laboratoire de Toxicologie Moléculaire, 45, rue des Saints Pères, 75006 Paris, France
    Med Sci (Paris) 25:21-4. 2009
    ..Targeting mTOR pathway overcomes resistance to EGFR inhibitors and produces a cooperative effect with EGFR inhibitors, providing a valid therapeutic strategy to be tested in a clinical setting...
  14. doi request reprint [Endometrial cancer in HNPCC syndrome]
    F Lecuru
    Service de Chirurgie Gynécologique et Cancérologique, Hopital Europeen Georges Pompidou, AP HP, Paris, France
    J Gynecol Obstet Biol Reprod (Paris) 37:547-53. 2008
    ..Screening of endometrial cancer remains the main objective of the management of those patients. Endometrial biopsy should have a larger place...
  15. ncbi request reprint Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors
    R Hamelin
    Laboratoire de Genetique des Tumeurs, Institut Curie, Paris, France
    Oncogene 8:2213-20. 1993
    ..The computer program was found to be reliably predictive. This DGGE procedure appears thus to be effective and reliable for detecting mutations in exons 5-8 of the p53 gene...
  16. doi request reprint KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    Astrid Lievre
    L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 26:374-9. 2008
    ..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
  17. doi request reprint Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
    T Andre
    Department of Medical Oncology, Hopital Saint Antoine, Universite Paris VI, Paris, France
    Ann Oncol 24:412-9. 2013
    ....
  18. ncbi request reprint Oncogenic mutations as predictive factors in colorectal cancer
    A Lievre
    INSERM UMR S 775 Molecular Basis of Response to Xenobiotics, Paris, France
    Oncogene 29:3033-43. 2010
    ....
  19. doi request reprint [Predictive factors of response to anti-EGFR treatments in colorectal cancer]
    Astrid Lievre
    Inserm UMR S775, Bases Moléculaires de la Réponse aux Xénobiotiques, Universite Paris Descartes, 45, rue des Saints Pères, 75006 Paris, France
    Bull Cancer 95:133-40. 2008
    ....
  20. ncbi request reprint Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer
    C Rosty
    Services d anatomie pathologique, Hopital Laennec, Paris, France
    Mod Pathol 13:586-90. 2000
    ..In agreement with mouse models for HNPCC, these results suggest the involvement of alternative mechanisms to complete mismatch repair deficiency for lymphomagenesis in HNPCC syndrome...
  21. ncbi request reprint Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma
    S Olschwang
    Fondation Jean Dausset CEPH, Paris, France
    Hum Mutat 12:424-30. 1998
    ....
  22. ncbi request reprint Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    Geraldine Perkins
    Institut National de la Recherche et de la Santé Médicale, UMR S775, Paris, France
    Int J Cancer 127:1321-31. 2010
    ..Our results suggest the importance of EGFR downstream signaling phosphoproteins expression in addition to KRAS status to define the subgroup of patients who will not benefit from anti-EGFR therapy...
  23. ncbi request reprint Genetics of hepatocellular tumors
    P Laurent-Puig
    INSERM, U775, Bases Moléculaires de la Réponse aux Xénobiotiques, Paris, France
    Oncogene 25:3778-86. 2006
    ..These classifications have clinical relevance as genetic alterations may also be related to prognosis...
  24. doi request reprint Genetics: Predictive value of KRAS mutations in chemoresistant CRC
    Astrid Lievre
    INSERM Laboratory, Paris, France
    Nat Rev Clin Oncol 6:306-7. 2009
    ..KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer...
  25. doi request reprint [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]
    Pierre Laurent-Puig
    Universite Paris Descartes, Inserm UMR S U775 Bases moléculaires de la réponse aux xénobiotiques, Hopital Europeen Georges Pompidou, pole de biologie, Pôle de Cancérologie
    Bull Cancer 95:935-42. 2008
    ....
  26. doi request reprint Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study
    F Lecuru
    Department of Gynecological and Oncological Surgery, Georges Pompidou European Teaching Hospital, Paris, France
    Int J Gynecol Cancer 18:1326-31. 2008
    ..However, diagnostic hysteroscopy ensured the diagnosis of endometrial adenocarcinoma in HNPCC women with bleeding. Nevertheless, usefulness and optimal modalities of screening remain to be determined...
  27. pmc Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
    R A Bras-Goncalves
    Institut Curie, UMR 147 CNRS Institut Curie, Paris, France
    Br J Cancer 82:913-23. 2000
    ....
  28. ncbi request reprint Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity
    P Legoix
    Centre d Etude du Polymorphisme Humain, INSERM U434 Laboratoire de Génétique des Tumeurs, Fondation Jean Dausset CEPH, Paris, France
    Oncogene 18:4044-6. 1999
    ..The first mechanism implies a beta catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes...
  29. doi request reprint K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy
    Marie Christine Etienne-Grimaldi
    Oncopharmacology Department, Centre Antoine Lacassagne, Universite Rene Descartes, Paris, France
    Clin Cancer Res 14:4830-5. 2008
    ..Because combinations of anti-EGFR with 5-fluorouracil (5-FU)-based chemotherapy are promising treatments, we analyzed the effect of K-Ras mutations in patients having received exclusive 5-FU therapy...
  30. pmc BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group
    D Stoppa-Lyonnet
    Unité de Génétique Oncologique and Unité INSERM U 434, Paris, France
    Am J Hum Genet 60:1021-30. 1997
    ..In addition, 15 DNA variants (14 missense mutations and 1 neutral mutation) were identified, 9 of which were novel. Indirect evidence suggests that seven of these mutations are deleterious...
  31. ncbi request reprint Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy
    A Cabelguenne
    , , Paris, France
    Int J Cancer 93:725-30. 2001
    ..Our data suggest that GST enzymes are associated with larynx cancer and that their use as predictive factors and treatment targets should be further explored...
  32. ncbi request reprint UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
    Jean Francois Cote
    Institut National de la Sante et de la Recherche Medicale UMR S775, Bases Moléculaires de la Réponse aux Xénobiotiques, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, France
    Clin Cancer Res 13:3269-75. 2007
    ....
  33. ncbi request reprint Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
    Sandrine Boyault
    INSERM U674, CEPH Fondation Jean Dausset, Paris, France
    Hepatology 45:42-52. 2007
    ..G5 and G6 were strongly related to beta-catenin mutations that lead to Wnt pathway activation; in particular, G6 tumors were characterized by satellite nodules, higher activation of the Wnt pathway, and E-cadherin underexpression...
  34. ncbi request reprint Pharmacogenetics of acenocoumarol pharmacodynamics
    Sandrine Morin
    Pharmacology Department, Saint Antoine University Hospital, Paris, France
    Clin Pharmacol Ther 75:403-14. 2004
    ..The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic polymorphisms to the interindividual variability of acenocoumarol pharmacodynamic response...
  35. doi request reprint A genetic study of the role of the Wnt/beta-catenin signalling in Paneth cell differentiation
    Pauline Andreu
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
    Dev Biol 324:288-96. 2008
    ..Overall, our findings show that a high level of beta-catenin activation is required to determine Paneth cell fate and that fine tuning of beta-catenin signalling is critical for correct Paneth cell lineage...
  36. doi request reprint Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis
    Antoine Legras
    INSERM, U775, Paris, France
    Int J Cancer 122:2242-8. 2008
    ..Considering their high frequency in colorectal adenomas, mitochondrial D310 mutations could represent a biomarker for early detection of CRC although their causative role in colorectal carcinogenesis remains uncertain...
  37. ncbi request reprint CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
    Dany Anglicheau
    Unité INSERM UMR S490, Centre Universitaire des Saints Peres, Paris, France
    Clin Pharmacol Ther 75:422-33. 2004
    ..We postulated that, in renal transplant recipients, these SNPs could be associated with interindividual variations in cyclosporine pharmacokinetics...
  38. ncbi request reprint Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
    Laurent Bodin
    Institut National de la Sante et de la Recherche Medicale, Unité Mixte de Recherche Scientifique, University Rene Descartes, Paris, France
    Blood 106:135-40. 2005
    ....
  39. doi request reprint Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents
    Nicolas Goasguen
    Department of Gastroenterology, Universite Paris V, Laboratoire de Toxicologie Moléculaire, Inserm UMR S775 and AP HP, Hopital Europeen Georges Pompidou, Paris, France
    Int J Cancer 127:1028-37. 2010
    ..Our results demonstrate intermetastatic and intrametastatic heterogeneity suggesting that pretherapeutic analysis of a single tumor biopsy is likely to lead to a misinterpretation of sensitivity to anticancer treatment...
  40. doi request reprint No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer
    Karine Pallier
    INSERM, UMR S775, Paris, France
    Mol Carcinog 48:581-5. 2009
    ..In conclusion, we do not deny the possible involvement of PXN in cancer but our findings do not support a major role for PXN somatic changes in lung carcinogenesis...
  41. pmc Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma
    Astrid Lievre
    INSERM U775 et Université René Descartes, Paris, France
    BMC Cancer 6:270. 2006
    ....
  42. ncbi request reprint Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts
    Fariba Nemati
    Preclinical Investigation Laboratory, Department of Translational Research, Hopital Europeen Georges Pompidou, Paris, France
    Anticancer Drugs 20:932-40. 2009
    ..In conclusion, this panel of human NSCLC xenografts reliably reproduces the data obtained in patient tumors and the relative sensitivity to docetaxel reported in NSCLC patients...